Conference abstract · 17 Jul 2017
Conference abstractPublished 27 Jul 2015
Data management in pharmacovigilance
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
The World Health Organization (WHO) defines pharmacovigilance as the science and activities relating to the detection, evaluation, understanding, and prevention of adverse reactions to medicines or any other medicine-related problems. In 1893, The Lancet first reported an established drug safety reporting system for suspected adverse drug reactions (ADRs). Since then, the definition and scope of pharmacovigilance have evolved as a systems approach. Pharmacovigilance is a highly sensitive field as it involves monitoring of the safety of medicines and taking action to reduce risk and increase benefit. The pharmacovigilance data management starts with the data collection and, it is imperative to address the report origin, triage cases, enter information in drug safety database, make medical assessment, request report follow-up information and mode for regulatory submissions. All these stages require a high and complex degree of technical skill and judgment to ensure that accurate conclusions and right decisions are made during the establishment of benefit-risk profile for a product. A poor pharmacovigilance data management not only jeopardizes patient safety, it also increases the risk of investing in the development of wrong product which causes a huge loss to a pharmaceutical company. Therefore, it is very important to establish a robust pharmacovigilance data management system which complies with the stringent regulatory guidelines, global pharmaceutical norms and ultimately safeguard the pharmacovigilance end users, the patient. An ideal model would be implementation of business management software (e.g. Microsoft Dynamics NAV/ SAP ERP) for better data management, process harmonization, enhanced data security and reduction in delay due to high manual dependence.
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Conference abstract · 27 Jul 2015
Data Management in Pharmacovigilance
Opinion · 29 Nov 2025
Pharmacovigilance: Modern Safety, Real- World Data, AI
Article · 24 Dec 2024
Extracting Clinical Insights from Pharmacovigilance Data: Identifying Drug Interactions and Population-Specific Risks
Conference abstract · 28 Aug 2024
Real-world safety data of the orphan drug Onasemnogene Abeparvovec (Zolgensma®) for the SMA rare disease: a pharmacovigilance study based on the EMA adverse event reporting system
More from this journal
The newest in Journal of Clinical Trials.
Case report · 10 Aug 2026
Tuberculosis Associated Spondylolisthesis and Radiculopathy
Short communication · 31 Jul 2026
Understanding Bioavailability as a Key Element in Effective Therapeutic Delivery
Research article · 14 Jun 2026
Ensuring Rights and Dignity in Ethical Practices of Clinical Studies with Vulnerable Group and Safeguarding Vulnerable Group Act (2006)
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Clinical Trials
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Ajay Francis Christopher”

